Standards & Regulation

Is pharma putting women and children last?

A recent review and meta-analysis highlights the huge impact of fake and substandard drugs.

“Right to Try” legislation may have compassion at its heart, but it does not do enough to ensure patient protection.

Fighting counterfeit medicines is a noble goal, but the financial burden of safety features may affect access to medicines in unintended ways.

Interest in cannabinoid drug development is growing. The potential market – and the opportunity to treat unmet patient needs – is enormous.

How will biopharmaceutical process development be affected by next-generation technologies?

Why are we still making life difficult for a growing patient population when solutions exist?

Do methods that compare newly approved drugs with those already on the market help cut healthcare costs?

Most, but not all, UK pharma companies are on track to keep their medicines on the European market by March, 2019.

Thought that most companies understood good manufacturing practice? Think again – there are always a few bad eggs.